SUBSCRIBE
SUBSCRIBE
News   Policy

Amgen Expects FDA to Set Panel Review of Bone Drug

June 10, 2009 | 
1 min read
Bookmark and Share

Reuters -- Amgen Inc expects the U.S. Food and Drug Administration to call for an advisory panel of osteoporosis experts to review its marketing application for experimental bone drug denosumab.

Regulatory
Amgen Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Human brain with abstract visualization of neuron activity
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
Donald Trump sits at a desk holding up a piece of paper he just signed while a crowd of people applauds
Government
Trump’s Tax Law Restores Orphan Drug Exemptions, Cuts Medicaid, Threatens 340B Program and Gives PBMs a Pass
July 8, 2025
 · 
3 min read
 · 
Tristan Manalac
Health and Human Services Secretary Robert F. Kennedy Jr. makes remarks at an event announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)
Legal
Medical Groups Sue RFK Jr. Over ‘Baseless and Uninformed’ Changes to COVID-19 Vaccine Policy
July 8, 2025
 · 
2 min read
 · 
Tristan Manalac